Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | RBP4 | P02753 | 8/20 | 0.40 |
| ▸ | TTR | P02766 | 7/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410383 | 0.85 | NOTUM (0.49) | NOTUMRBP4TTRDRD2DRD3 | |
| SCHEMBL1410132 | 0.80 | NOTUM (0.58) | NOTUMTSHR | |
| SCHEMBL1410170 | 0.75 | DPP4 (0.47) | KDM4EALDH1A1NOTUMRBP4SMN1; SMN2 | |
| SCHEMBL1410348 | 0.72 | NOTUM (0.49) | NOTUMP2RX7 | |
| SCHEMBL31042538 | 0.71 | CHRM4 (0.49) | KDM4EALDH1A1NOTUMSMN1; SMN2DRD2 | |
| SCHEMBL1410084 | 0.70 | NOTUM (0.44) | NOTUMP2RX7 | |
| SCHEMBL2517376 | 0.70 | NOTUM (0.48) | NOTUMRBP4TTRP2RX7 | |
| SCHEMBL31458523 | 0.69 | TSHR (0.60) | KDM4EALDH1A1NOTUMTSHRPOLB | |
| Potassium Ion SCHEMBL1409563 | 0.68 | NOTUM (0.44) | NOTUMP2RX7 | |
| SCHEMBL9218378 | 0.68 | ACHE (0.64) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295406-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-8338622-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2295406-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | NES, BMI1, DOT1L | KDM4E 641/4885ALDH1A1 270/4885NOTUM 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.